Discovery of carmegliptin: A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
- 1 February 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (3), 1109-1113
- https://doi.org/10.1016/j.bmcl.2009.12.024
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- In silico prediction of brain and CSF permeation of small molecules using PLS regression modelsEuropean Journal of Medicinal Chemistry, 2008
- 1,3-Disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituentsBioorganic & Medicinal Chemistry Letters, 2004
- Asymmetric synthesis of A-factorJournal of the Chemical Society, Perkin Transactions 1, 1998
- The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivoToxicology, 1996
- Syntheseversuche in der Emetin‐Reihe. 1. Mitteilung. 2‐Oxo‐hydrobenzo[a]chinolizineHelvetica Chimica Acta, 1958